Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban in Outpatients with Acute COVID-19
NCT04508023Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rivaroxaban in coronavirus disease 2019 (COVID-19), sponsored by Janssen Pharmaceutical. Started Aug 2020; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04508023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508023.